Pharmaceutical manufacturers of Vancomycin

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

Concord Biotech Limited is a prominent vertically integrated, research and development-driven biotechnological powerhouse that produces Active Pharmaceutical Ingredients using fermentation and semi-synthetic methods, as well as Finished formulations. Established in 2000, Concord has evolved from a single-product enterprise to a wide-ranging solution provider, offering products across varied therapeutic segments. Concord is internationally recognized for its products and holds a strong presence in over 50 countries worldwide with effective distribution infrastructure in markets such as North America, Europe, Japan, Central & Latin America, Africa, Australia, and other regions.

Transo-Pharm, a fully authorized and accredited distributor, specializes in pharmaceutical components for the medical and veterinary sectors. It provides assistance to customers throughout the entire API life cycle, from product innovation to sales. Transo-Pharm acts as a sourcing and regulatory marketing representative for API producers. It assists customers in establishing DMFs and offers GMP advisory services. With a dedicated regulatory division, a storage facility, proprietary IPs for API procedures, and collaborations with research facilities, Transo-Pharm offers a broad array of services. It operates from its establishments in Shanghai, Hong Kong, Singapore, and the United States.

Mac-Chem has a National and Global footprint with a wide presence across the globe. Mac-Chem has carved a niche for itself in the exceedingly competitive and quality conscious sphere of Active Pharmaceutical Ingredients (API) manufacturing with US-FDA, EDQM, COFEPRIS, ANVISA, MFDS-Korea, WHO-GMP and ISO certified facilities

Haorui, established in the year 1997, operates as a manufacturer and provider of APIs, pharmaceutical intermediates, veterinary products, and food additives. Furthermore, it aids international pharmaceutical firms in achieving domestic registration for their finished dosage forms to support their global expansion efforts. The company's array of USFDA approved products includes Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, and Dasatinib Monohydrate among others. Its headquarters is situated in Shenzhen, China, while it maintains four manufacturing sites in Hubei, Zhejiang, Jiangxi, and Henan. The Hubei facility is recognized for its USFDA and EU GMP approvals, specializing in the production of high potency and oncology materials within a dedicated oncology workshop, meeting OEB 5 material production standards. Haorui prides itself as a dependable partner for all your pharmaceutical needs.

NCPC International Corp. is a platform for international trade of NCPC and the exclusive channel for exporting the preparations of NCPC, the business scope covers import and export trade, CMO, technology transfer and pharmaceutical logistics in domestic. NCPC International Corp. provides all-around and one-stop sales and service on APIs, preparations, medical equipments and consumables, based on creating more values for foreign customers. NCPC International Corp. has been exporting to more than 80 countries and regions, increasing the overseas sales yearly, ranking 1st on exporting preparations in china mainland for last continuous 3 years. NCPC International Corp. is a worldwide supplier of generic pharmaceuticals. As an Anti-infective expert and your local one- stop partner NCPC International Corp. will provide you the most comprehensive products and the most professional and efficient services. We are sincerely expecting to cooperate with friends from all sectors for shared development and a brighter future!

Xellia is a specialty pharmaceutical company focusing on providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions.

Livzon Group is a full-fledged pharmaceutical company that integrates the advancement and exploration, manufacturing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients (API), chemical medication, diagnostic reagents, and more. Recently, Livzon has shifted its strategic focus to research and development in antibody medications and vaccines, and has set up specialized laboratories for this purpose.

CKD Bio Corporation focuses on enhancing life through improved pharmaceuticals, drawing from a wealth of 80 years' experience in the industry. The company specializes in the production of top-quality intermediates and APIs, employing a comprehensive manufacturing process that encompasses fermentation and chemical synthesis

Livzon Group Fuzhou Fuxing Pharmaceutical Co Ltd (FFPC) was founded in 1979. Livzon Pharmaceutical Group Inc purchased FFPC in 2004, aiming to transform it into a top-notch API production center and R&D center. FFPC is a sizable pharmaceutical company with two facilities, Gutian Fuxing Pharmaceutical Co., Ltd and Fuqing Jiangyin site. FFPC has state-of-the-art machinery and advanced technology.

Chongqing Daxin Pharmaceutical Co., Ltd. (herein referred as Chongqing Daxin) was established in 1941. It is a core member of PKU HealthCare Industry，which has been praised as the Key High-tech Enterprise of the National Torch Program, Nationwide Key Enterprise in Chemical and Pharmaceutical Industry, one of the National Top 100 Pharmaceutical Enterprises and the Exportation brand leader enterprise supported by Chongqing government. After over 70 year's development, it has become a biotech oriented and comprehensive pharmaceutical company which covers areas of APIs and finished dosages.

Zhejiang Medicine currently has nine major subsidiaries, including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang LaiYi Medicine Co., Ltd., Zhejiang Novus Pharmaceuticals Co., Ltd., Zhejiang Changhai Pharmaceuticals Co., Ltd., Shanghai Vital Health Management Co., Ltd., NovoCodex Biopharmaceuticals. Co., Ltd., and two research units, the Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biopharmaceutical R&D Center. The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees.

Founded in 2018, Ceres F&D is a pharmaceutical company specializing in the production of high-quality and efficient medications. Our dedication to excellence is demonstrated through our continual adherence to the highest standards, the advancement of innovative technology, and the ongoing investment in new product developments.

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997. After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market. In October, the company's shares were then listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 960 million yuan in registered capital and total assets of 10 billion yuan. Company profile Zhejiang Medicine currently has nine major subsidiaries, including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang LaiYi Medicine Co., Ltd., Zhejiang Novus Pharmaceuticals Co., Ltd., Zhejiang Changhai Pharmaceuticals Co., Ltd., Shanghai Vital Health Management Co., Ltd., NovoCodex Biopharmaceuticals. Co., Ltd., and two research units, the Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biopharmaceutical R&D Center. The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees.